Detection of soluble adhesion molecules in pleural effusions

Area of Science:

• Immunology
• Oncology
• Biochemistry

Background:

• Immune functions like T cell activation and tumor cell lysis rely on cell adhesion molecules CD2/LFA-3 and LFA-1/ICAM-1.
• Soluble forms of LFA-3 (sLFA-3) and ICAM-1 (sICAM-1) can inhibit these immune processes.
• Understanding soluble adhesion molecule levels in effusions is crucial for diagnosing and understanding disease mechanisms.

Purpose of the Study:

• To investigate whether soluble LFA-3 (sLFA-3) and soluble ICAM-1 (sICAM-1) levels are elevated in malignant or inflammatory pleural effusions compared to transudates.
• To determine if specific cancer types are associated with higher levels of these soluble adhesion molecules.

Main Methods:

• Enzyme-linked immunoassays (ELISAs) were used to quantify sLFA-3 and sICAM-1 levels in pleural effusions from 70 patients.
• Effusions were categorized into transudates, inflammatory, malignant, and other types.
• Specific assays were performed to differentiate between the complete sLFA-3 molecule and its domain 1.

Main Results:

• Soluble ICAM-1 (sICAM-1) levels were elevated in all exudates (inflammatory and malignant) compared to transudates.
• Highest sICAM-1 levels were observed in malignant effusions, particularly those from mesotheliomas, non-small cell lung cancers, and gynecologic malignancies.
• Soluble LFA-3 (sLFA-3) levels were also elevated in malignant effusions but not in inflammatory effusions, and correlated with protein, cholesterol, LDH, and sICAM-1 levels.

Conclusions:

• Elevated levels of the complete sLFA-3 molecule are indicative of malignant pleural effusions.
• sICAM-1 levels are elevated in both inflammatory and malignant effusions, suggesting its role in generalized inflammation or tumor-associated processes.
• Secretion of sICAM-1 and sLFA-3 by tumor cells may impair T-cell-mediated anti-tumor immunity.